On October 3, 2025 Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody, to treat cancer, autoimmune and infectious diseases, reported the Company will present data on its Multabody approach at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 40th Annual Meeting taking place November 5-9, 2025 in National Harbor, MD (Press release, Radiant Biotherapeutics, OCT 3, 2025, View Source [SID1234656431]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Current multi-specific antibodies have shown promise as a family of targeted drugs, providing the potential for the simultaneous binding of two or more antigens or epitopes, however inherent structural limitations often prevent optimal therapeutic outcomes for complex diseases due to suboptimal binding affinity and specificity challenges. Radiant’s proprietary Multabody technology addresses these limitations by uniquely harnessing natural biological mechanisms to engage multiple disease targets with superior binding strength, precise tunability, and exceptional therapeutic breadth—all within a single engineered molecule. This breakthrough approach is particularly transformative for treating cancer, autoimmune, and infectious diseases, where the Multabody technology can direct immune cells to destroy tumors, block multiple disease pathways, or maintain therapeutic efficacy even as pathogens mutate.
Poster Presentation Details:
Title: Multabodies: A next-generation approach for cancer immunotherapy and 4-1BB agonist therapy
Abstract Number: 847
Session: Immune stimulants and immune modulators
Date/Time: Tuesday, November 4, 2025
Presenting Author: Joanne Hulme, Ph.D., Chief Scientific Officer, Radiant Biotherapeutics
The titles of the abstracts are currently available on the SITC (Free SITC Whitepaper) 2025 Abstracts webpage. All posters will be available on the virtual meeting platform beginning November 4, 2025, at 9 AM ET.